15 Undervalued Momentum Stocks That Are Taking Off

Page 12 of 14

3. Revolution Medicines Inc. (NASDAQ:RVMD)

Number of Hedge Fund Holders: 71

JPMorgan added Overweight-rated Revolution Medicines Inc. (NASDAQ:RVMD) to its “Positive Catalyst Watch” list as per a February 17 report. The development came ahead of the RASolute 302 second-line pancreatic ductal adenocarcinoma readout expected in H1 2026.

According to the report, JPMorgan is confident in Daraxonrasib, citing encouraging performance trends for the drug relative to the historical chemotherapy benchmark. The firm sees a positive outcome as median overall survival in the 9–10 months range, alongside a hazard ratio in the mid-0.6-low-0.7 range.

Before this update, early in the first week of February, JPMorgan analyst Brian Cheng had raised his price target on Revolution Medicines Inc. (NASDAQ:RVMD) by around 33% to $122 (from $92), citing updates to the company’s financial model. The firm maintained an Overweight rating.

Earlier, at the end of January, Oppenheimer analyst Jay Olson doubled his price target on the stock from $75 to $150, as the firm believes that Revolution Medicines Inc. (NASDAQ:RVMD) could be an attractive acquisition candidate in 2026, particularly as the company is expected to see multiple milestones this year.

Revolution Medicines shares have performed well, with over 140% returns in the past year and gains of 28% in 2026 as of February 20. However, the stock currently trades 18% below its 52-week high of $124.5.

Revolution Medicines Inc. (NASDAQ:RVMD) is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. It has several RAS(ON) inhibitors currently in clinical development, including daraxonrasib (RMC-6236).

Page 12 of 14